01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are...
20:10 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Youthful memories

Alkahest Inc. co-founder and Stanford University researcher Tony Wyss-Coray has followed up his earlier discovery of blood factors in the elderly that contribute to cognitive decline by finding an umbilical cord blood factor that may...
23:59 , Jan 10, 2017 |  BC Extra  |  Clinical News

Paper suggests Aravive compound could block Zika

In a study published Tuesday in Cell Reports , researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could protect glial cells from Zika infection. Aravive-S6 is an Fc-fusion protein...
19:41 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); breast cancer; ovarian cancer Cell culture and mouse studies suggest a GAS6 -binding AXL decoy could help treat AML and metastatic breast and ovarian cancers. The AXL decoy, Aravive-S6 ,...
20:46 , Dec 15, 2016 |  BC Innovations  |  Targets & Mechanisms

Keeping the Gas off AXL

With its development of an AXL decoy able to trap and sequester the native receptor’s ligand with femtomolar affinity, Aravive Biologics Inc. believes it has a biologic that can bypass the potency and selectivity issues...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AXL receptor tyrosine kinase (AXL; UFO); growth arrest-specific 6 (GAS6) In vitro and mouse studies suggest an AXL-Fc fusion protein could help prevent cancer...
07:00 , Mar 13, 2014 |  BC Innovations  |  Cover Story

Killer targets in metastasis

An international team has found a new pathway in NK cells that leads to the rejection of metastatic tumors. 1 It is still unclear which components of the pathway will make the best targets. The...
07:00 , Apr 25, 2013 |  BC Innovations  |  Targets & Mechanisms

MERTK: upstream from BRAF

U.S. researchers have shown that inhibiting c-Mer proto-oncogene tyrosine kinase, a protein that sits upstream from BRAF , reduced melanoma growth in mice. 1 Future studies will need to determine whether inhibitors of this kinase...